Engage Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Staccato Alprazolam 1 mg
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Engage Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03516305
- Locations
- 🇺🇸
Clinilabs Research Unit, Eatontown, New Jersey, United States
Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Engage Therapeutics, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT03478982
- Locations
- 🇺🇸
UAB Hospital, Birmingham, Alabama, United States
🇺🇸University of Arizona, Phoenix, Arizona, United States
🇺🇸St. Joseph's Hospital and Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States
News
No news found